22 May 2013
Keywords: myriad, mpc-0920, performs, well, ph, usa-based, biopharmaceutcal
Article | 04 February 2008
USA-based biopharmaceutcal firm Myriad Genetics has announced the completion of a Phase I trial of MPC-0920, its candidate oral direct
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 February 2008
© 2013 thepharmaletter.com